The phase 1 to 2 LIBRETTO 001 study, conducted in RET fusion positive NSCLC patients either previously treated with platinum-based chemotherapy or chemotherapy-naïve, showed encouraging results for selpercatinib, a novel inhibitor of RET kinase (18). This evidence concerns the gene RET and non-small cell lung carcinoma.